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The emergence of drug-resistant Streptococ-
cus pneumoniae underscores the need for timely,
local, population-based surveillance of antimicro-
bial resistance. The prevalence of resistance in
U.S. communities varies widely, with 2% to 53%
of S. pneumoniae isolates found to have reduced
susceptibility to penicillin (1-4). The Centers for
Disease Control and Prevention recommends
that empiric antibiotic therapy for pneumococcal
infections be based upon local susceptibility
patterns (2,5). However, few communities track
drug-resistant S. pneumoniae.
The Survey
To estimate the prevalence of drug-resistant
S. pneumoniae in New York City, we surveyed
hospital-based clinical microbiology laboratories
from 1993 to 1995. A standardized questionnaire
was mailed annually to each laboratory, and
those that did not respond were contacted by
telephone or were visited. To evaluate
compliance with S. pneumoniae penicillin
susceptibility testing guidelines established by
the National Committee for Clinical Labora-
tory Standards (NCCLS) (6), we asked about
criteria for selecting specimens and techniques
for oxacillin disk diffusion screening and
determination of penicillin MICs.
To determine the prevalence of penicillin
resistance, we asked for the number of S.
pneumoniae isolates identified during the year,
the number tested for susceptibility to penicillin,
and the number found to be possibly resistant by
the oxacillin disk diffusion test and penicillin-
intermediate or -resistant by MIC testing. We
also asked that information be provided
separately for isolates from normally sterile sites
(e.g., blood, cerebrospinal fluid) and from
nonsterile sites (e.g., sputum, nasopharyngeal
swab). In 1995, we added questions regarding the
MIC test results for extended-spectrum cepha-
losporins (ESCs), including the number of
penicillin-nonsusceptible isolates that were also
nonsusceptible to an ESC. No individual patient
information was obtained. A report summariz-
ing the results of the survey and describing
NCCLS guidelines was mailed annually to
microbiology laboratories, hospital infection
control departments, and local infectious
disease physicians and pediatricians.
Analysis
Of 67 hospital-based clinical microbiology
laboratories in New York City, 100% completed
the survey in 1993, 98% in 1994, and 100% in
1995. Overall, more than 5,000 S. pneumoniae
isolates were reported annually.
Data were analyzed by using EpiInfo Version
6.0 (CDC, Atlanta, GA, USA). Drug-susceptibility
results are presented for laboratories that
conformed with NCCLS guidelines and provided
complete data on all S. pneumoniae isolates
identified (Table 1).
Susceptibility Criteria
The NCCLS recommends routine screening
by the oxacillin disk diffusion test of clinically
important  S. pneumoniae isolates for susceptibil-
ity to penicillin. Isolates with a zone size £ 19 mm,
or any isolate from the blood or cerebrospinal
fluid, should be tested with an approved MIC
method such as broth dilution or antibiotic gradient
strips (e.g., E-test). Isolates whose penicillin
MICs are either intermediate (MIC ³ 0.1 and  £ 1
mg/ml) or resistant (MIC ³ 2 mg/ml) should also
have MICs determined for susceptibility to an
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ESC such as cefotaxime or ceftriaxone (ESC-
intermediate MIC = 1 mg/ml; ESC-resistant
MIC ³ 2 mg/ml) (6). We will use the term
“nonsusceptible” to refer to both intermediate
and resistant isolates.
Findings
The proportion of laboratories conforming
with NCCLS guidelines for penicillin susceptibil-
ity testing of S. pneumoniae increased from 22%
in 1993 to 69% in 1995. This was due to an
increase in the number of laboratories that
screened all isolates, a sharp decrease in the use
of automated MIC tests, and a fourfold rise in the
use of antibiotic gradient strips for determining
MICs (Table 2). Overall, the proportion of isolates
with oxacillin disk diffusion test zone size £ 19
mm, suggesting possible resistance, increased
from 8.5% of isolates in 1993 to 20.2% in 1995
(Table 1). MIC test results showed that 5.7% of
isolates were penicillin-intermediate and 1.5%
penicillin-resistant in 1993, compared with 8.8%
and 6.3%, respectively, in 1995. The prevalence of
resistant organisms increased among isolates
from both sterile and nonsterile sites and was
somewhat higher among nonsterile-site isolates
than among sterile-site isolates in 1995 (6.9% vs.
4.9%, Chi-square p = 0.03).
Seven of the laboratories followed NCCLS-
recommended methods and provided complete
penicillin susceptibility results for both 1993 and
1995. These seven reported that among 779
isolates in 1993, 25 (3.2%) were intermediate and
six (0.8%) were resistant to penicillin. Among 896
isolates in 1995, 83 (9.2%) were intermediate, and
47 (5.2%) were resistant.
The prevalence of penicillin resistance varied
between laboratories and by geographic area. At
Table 1. Penicillin resistance among Streptococcus
pneumoniae isolates at New York City hospital laboratories
1993 1994 1995
No. of isolates No. (%) No. (%) No. (%)
Screened with
  oxacillin diska 3,227 4,133 4,912
zone size £ 19 mmb    273 (9)    549 (13)    995 (20)
Screened and
  confirmed with
  approved MICc 1,229 2,491 3,535
zone size £ 19 mm    154 (13)    350 (14)    704 (20)
Id      70 (6)    209 (8)    310 (9)
Rd      19 (2)    115 (5)    222 (6)
Sterile-site isolates
  screened and
  confirmed with MICe      462     649 1,321
I      16 (3)      66 (10)      83 (6)
R        5 (1)      20 (3)      65 (5)
Nonsterile isolates
  screened and
  confirmed with MICf    456    662 1,596
I      12 (3)      83 (13)    200 (13)
R        5 (1)      31 (5)    110 (7)
aNumber of laboratories reporting oxacillin disk diffusion test
results in 1993, 1994, 1995 was 33, 40, 51, respectively.
bOxacillin disk diffusion test zone size.
cApproved penicillin MIC tests include antibiotic gradient
strips and broth dilution or micro-dilution using Mueller-
Hinton broth supplemented with 2-5% lysed horse blood.
Number of laboratories reporting MIC test results in 1993,
1994, 1995 was 10, 22, 35, respectively.
dI=Penicillin-intermediate (MIC ³ 0.1 and £ 1.0 mg/ml);
R=Penicillin-resistant (MIC ³ 2.0 mg/ml).
eNumber of laboratories reporting sterile site isolate results
in 1993, 1994, 1995 was 8, 12, 32, respectively.
fNumber of laboratories reporting nonsterile site isolate results
in 1993, 1994, 1995 was 5, 9, 28, respectively.
Table 2. Penicillin susceptibility testing protocols for
Strepococcus pneumoniae in New York City hospital
laboratories
1993 1994 1995
No. of laboratoriesa No. (%) No. (%) No. (%)
Screened with
  oxacillin disk 55 (82) 63 (97) 65 (97)
Screened all isolates 38 (57) 56 (86) 59 (88)
Screened only sterile   9 (13)   6 (9)   6 (9)
Other   8 (12)   1 (2)   0
Performed penicillin 39 (58) 51 (78) 56 (84)
  MIC test
MIC-tested
All isolates 10 (15)   9 (14)   7 (10)
Oxacillin-
  resistant only 18 (27) 39 (60) 42 (63)
Sterile isolates
  only   5 (7)   1 (2)   0 (0)
By request only   4 (6)   1 (2)   5 (7)
Other   2 (3)   1 (2)   2 (3)
Penicillin MIC techniqueb
Antibiotic gradient
  stripc 11(16) 41 (63) 50 (75)
Automated testsc 21 (31)   9 (14)   2 (3)
Broth dilution   8 (12) 11 (17)   5 (7)
Unknown   2 (3)   3 (5)   0
Conformed with
  NCCLS guidelinesd 15 (22) 38 (58) 46 (69)
aTotal number of laboratories responding to survey in 1993,
1994, 1995 was 67, 65, 67, respectively.
b13 laboratories used more than one MIC technique.
cAntibiotic gradient strip: e.g., E-test. Automated tests: e.g.,
Microscan, Vitek.
dNCCLS=National Committee for Clinical Laboratory
Standards. Screened all S. pneumoniae isolates with oxacillin
disk diffusion test and confirmed resistance with approved
penicillin MIC test.115 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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35 laboratories in 1995, 0% to 80% (median
13.1%) of isolates were nonsusceptible to
penicillin. Laboratories in the New York City
borough of Manhattan reported that 18% of
isolates were nonsusceptible to penicillin,
compared with 16% in Queens, 14% in the Bronx,
and 10% in Brooklyn (MIC data from Staten
Island were not available).
In 1995, 18 laboratories reported that of 275 S.
pneumoniae isolates nonsusceptible to penicillin,
90 (33%) were also nonsusceptible to an ESC.
Limitations
The survey design had several limitations.
First, levels of expertise varied among laborato-
ries regarding antibiotic susceptibility testing of
pneumococci. Laboratory variation may partly
account for the wide range in the proportion of
isolates nonsusceptible to penicillin observed at
individual laboratories, which could in turn
influence citywide estimates. We did not collect
and test isolates to confirm laboratory results.
Second, the number of laboratories included in
our results increased each year as more
laboratories adopted NCCLS methods and
provided complete data. This improved the
accuracy of the survey but made interpreting
trends difficult. Third, citywide estimates
inevitably mask important differences in the risk
for drug-resistant S. pneumoniae infections in
specific subpopulations; for example, day-care
attendance and prior antibiotic use have been
associated with drug-resistant pneumococcal
infections in children (1,7). Finally, since
information was collected on isolates, rather than
individual patients or infections, actual disease
incidence could not be calculated.
Conclusions and Recommendations
Our results document a marked improve-
ment in penicillin susceptibility testing protocols
for S. pneumoniae during this period. Because of
an increase in the proportion of isolates tested
and widespread adoption of antibiotic gradient
strips for MIC testing, more than two-thirds of
laboratories conformed with NCCLS guidelines in
1995, compared with fewer than one-fourth in 1993.
The survey demonstrates that drug-resistant
pneumococci are prevalent and may be increasing
in New York City. Penicillin resistance increased
fourfold between 1993 and 1995, and data from
1996 indicate that it has remained at this level or
continued to increase. Nine percent of blood
isolates in 1996 were intermediate and 6%
resistant to penicillin (New York City Depart-
ment of Health, unpub. data), compared with 6%
and 5%, respectively, among sterile-site isolates
in our survey for 1995. The proportion of S.
pneumoniae isolates resistant to penicillin in
New York City was similar to U.S. national
averages during this period (2-4). Our finding
that 33% of penicillin-nonsusceptible S.
pneumoniae isolates were resistant to ESCs is
also similar to the 29% (4) observed nationally.
On the basis of these results, we recom-
mended that New York City clinicians consider
carefully the possibility of penicillin and ESC
resistance when treating suspected S. pneumoniae
infections. Although the response to therapy may
vary by route of administration, site of infection,
and age and immune status of the patient,
treatment failure is increasingly common and
can have serious consequences (8,9). Educational
efforts are needed to promote appropriate use of
antibiotics and encourage use of the 23-valent
pneumococcal vaccine in populations at in-
creased risk for pneumococcal disease (10).
This laboratory survey was a relatively low-
cost method of estimating the prevalence of drug-
resistant pneumococci in New York City. It may
serve as a model in areas where clinical
laboratories routinely perform drug-susceptibil-
ity testing but the resources to collect or test
isolates centrally for surveillance are limited.
Despite the survey’s limitations, the estimates
provided may be sufficient to guide clinicians in
selecting appropriate empiric therapy for sus-
pected pneumococcal infections. Considerable
effort was spent each year disseminating these
data to laboratories, hospital infection control
departments, infectious disease physicians,
pediatricians, and other primary care physicians.
Our ability to expand this survey approach
beyond S. pneumoniae, penicillin, and ESCs is
limited by constraints on hospital laboratory staff.
As laboratories computerize and standard formats
are developed for the electronic transmission of
laboratory test results, collection and dissemina-
tion of susceptibility data will be possible on a wider
range of pathogens and antimicrobial drugs.
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